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ARTICLE OPEN
Comparing health status between patients with COPD in
primary, secondary and tertiary care
Mieke M. de Klein1, Jeannette B. Peters 2, Alex J. van ’t Hul3, Reinier P. Akkermans1,4, Johannes C. in ’t Veen5, Jan H. Vercoulen2,3,
Erik W. Bischoff1 and Tjard R. Schermer 1,6✉
In this study, we compare health status between COPD patients treated in three different care levels in the Netherlands and assess
determinants that influence their health status. We applied the Nijmegen Clinical Screening Instrument to measure eight health
status subdomains in primary (n= 289), secondary (n= 184) and tertiary care (n= 433) COPD patient cohorts. Proportions of
patients with severe problems in ≥3 subdomains are 47% in primary, 71% in secondary and 94% in tertiary care. Corrected for
patient characteristics, differences between the care levels are statistically significant for nearly all health status subdomains. The
pooled cohort data show female sex, age, FEV1 % predicted and BMI to be determinants of one or more subdomains. We conclude
that the proportion of COPD patients with severe health status problems is substantial, not just in tertiary care but also in primary
and secondary care. Use of detailed health status information may support patient-tailored COPD care.
npj Primary Care Respiratory Medicine           (2020) 30:39 ; https://doi.org/10.1038/s41533-020-00196-7
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a preventable
and treatable condition that is characterized by airflow limita-
tion1,2 and is now recognized to be a complex multi-systemic
disease3. The goal of COPD assessment is not only to determine
the level of airflow obstruction but also the impact of the disease
on the patient’s health status (HS). It is well known that there is
only a weak correlation between airflow obstruction, symptoms,
impairment and quality of life4,5. Because of this weak correlation,
it is important to focus on the overall of patients with COPD, which
consists of four domains: physiological problems, symptoms,
impairment in daily functioning, and quality of life6.
In several countries around the world (e.g. United Kingdom,
United States, Japan, the Netherlands), patients with COPD are
treated in primary care by general practitioners (GPs), in secondary
care by hospital-based chest physicians and in tertiary care
settings (i.e. pulmonary rehabilitation) by multidisciplinary teams
led by chest physicians. In the Netherlands, the care for COPD
patients is ‘demand-driven’7, which means that treatment is
tailored to the specific needs of an individual patient. In order to
do so, a detailed assessment of HS is a prerequisite.
While the majority (82%) of patients with COPD in the
Netherlands are treated in primary care8, most of our current
understanding of the clinical features and HS in COPD is based on
cohorts of patients who have been recruited from secondary and/
or tertiary care settings9. Consequently, it is largely unknown how
HS differs between patients with COPD who are treated in primary
care, secondary care and tertiary care, respectively. It is generally
assumed that COPD patients in primary care do not experience
substantial problems in their HS compared to patients who are
treated in secondary or tertiary care. Thus the aims of the present
study were to (i) compare HS between patients with COPD treated
in primary, secondary and tertiary care and (ii) to assess patient
characteristics (including physiological functioning) that poten-
tially influence HS in patients with COPD.
RESULTS
Study population
A total of 906 patients were included in the study. Table 1 shows
the characteristics of the patients in the primary, secondary and
tertiary care cohorts. Compared to the primary and secondary care
cohorts, there were more women than men in the tertiary care
cohort. Forced expiratory volume in 1 s (FEV1) % predicted was
lowest in the tertiary care cohort. In all three cohorts, >50% of the
patients showed overweight or obesity.
Differences in HS between the cohorts
Table 2 shows the mean scores on the Nijmegen Clinical
Screening Instrument (NCSI) subdomains for the three COPD
cohorts. On all subdomains, statistically significant differences
were found between the patients who were treated in primary,
secondary and tertiary care, respectively. Overall, tertiary care
patients reported significantly higher scores on all NCSI sub-
domains compared to primary and secondary care patients, and
secondary care patients reported significantly higher mean scores
on all subdomains compared to primary care patients.
After correcting for sex, age, body mass index (BMI) and FEV1 %
predicted in the mixed model analysis (Table 3), statistically
significant differences between the three patient cohorts
remained for all NCSI subdomains, except for the subdomain
‘General Quality of Life’ between the primary and secondary care
cohorts and the subdomain ‘Satisfaction with relations’ between
the primary and secondary cohorts and the secondary and tertiary
care cohorts.
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Severity of HS problems per care level
Figure 1 shows the distribution of patients with scores in the
range of normal functioning, mild problems and severe problems
for each subdomain of HS in the three cohorts. Overall, in all HS
subdomains the proportion of severe problems was substantially
higher in the tertiary care (pulmonary rehabilitation) cohort than
in the primary and secondary care cohorts. Increase in the
proportions with severe problems when comparing between
primary and secondary care cohort was also noted.
In the primary care cohort, 21% (60/289) of the patients reported
no severe problems in any of the subdomains, whereas 2%
reported severe problems in all NCSI subdomains (Fig. 2). In the
secondary care cohort, 11% (20/184) reported no severe problems,
whereas 9% reported severe problems in all subdomains. For
tertiary care, these percentages were 1% (4/433) and 17%,
respectively. Severe problems in three or more subdomains of HS
were reported by 47% of the patients in primary care, 71% of the
patients in secondary care and 94% of the patients in tertiary care
(Fig. 2).
Determinants of HS in the pooled cohort data
The mixed model analysis showed that female patients reported
statistically significant more problems in the subdomains ‘Beha-
vioural impairment’ and ‘Subjective symptoms’ compared to male
patients (Table 4). Patients who were younger reported statistically
significant more problems in the subdomains ‘General Quality of
Life’ and ‘Health-related Quality of Life’, ‘Satisfaction with
relations’, ‘Dyspnoea emotions’ and ‘Fatigue’ compared to older
patients. Patients who were older reported significantly more
problems in the subdomain ‘Behavioural impairment’ compared
to younger patients. Patients with higher BMI values reported
significantly more problems in the subdomains ‘Health-related
Quality of Life’, ‘Behavioural impairment’, ‘Dyspnoea emotions’
and ‘Fatigue’ compared to patients with a lower BMI. Finally,
patients with lower FEV1 % predicted values reported significantly
more problems in the subdomains ‘Subjective impairment’,
‘Behavioural impairment’ and ‘Subjective symptoms’ compared
to patients with a higher FEV1 % predicted value.
DISCUSSION
The main aim of this study was to compare HS between patients
with COPD treated in primary, secondary and tertiary care. We also
studied several patient characteristics that may be associated with
COPD patients’ HS. In the primary as well as in the secondary care
cohorts, the proportion of patients with multiple severe HS
problems was substantial. Implications of these results are that a
substantial part of COPD patients in primary care may require
Table 1. Patient characteristics of the primary, secondary and tertiary









(n= 289) (n= 184) (n= 433)
Sex, % male (n) 55 (159) 58 (106) 45 (196) 0.005
Age, years 64.5 ± 10.6 63.9 ± 9.5 60.7 ± 8.4 <0.001




11.4 (33) 21.7 (40) 19.9 (86)
Normal weight,
% (n)
33.9 (98) 24.5 (45) 28.0 (121)
Overweight, %(n) 33.6 (97) 26.6 (49) 30.8 (133)
Obese, % (n) 21.1 (61) 27.2 (50) 21.3 (92)
FEV1 %
predicteda, %
68.5 ± 16.8 63.9 ± 19.1 44.2 ± 19.1 <0.001
Data are presented as percentage (number) or mean ± standard deviation;
BMI= body mass index (underweight: <21, normal weight: 21–25, over-
weight: 25–30, obese: >30).
aFEV1 % predicted known: primary care cohort n= 279 (96.5%), secondary
care cohort n= 173 (94.0%), tertiary care cohort n= 431 (99.5%).
bp value from ANOVA test for continuous variables and Chi-square test for
categorical variables.
Table 2. Comparison of health status subdomains as measured by the NCSI between COPD patients treated in primary care, secondary care and
tertiary care.
Subdomaina Study population p valueb
Primary care cohort (n= 289) Secondary care cohort (n= 184) Tertiary care cohort (n= 433)
Mean ±SD 95% CI Mean ±SD 95% CI Mean ±SD 95% CI
Quality of life
General Quality of Life 17.2 15.9 15.4–19.1 21.3 16.2 18.9–23.7 28.8 14.9 27.4–30.2 <0.01
Health-related QoL 4.2 1.8 4.0–4.4 5.0 2.0 4.7–5.3 6.1 1.7 6.0–6.3 <0.01
Satisfaction relations 3.0 1.6 2.8–3.2 3.6 2.0 3.3–3.9 3.9 2.0 3.7–4.1 <0.01
Functional impairment
Subjective impairment 9.2 4.7 8.6–9.7 12.5 5.8 11.6–13.3 17.2 5.3 16.7–17.7 <0.01
Behavioural impairment 10.5 11.3 9.2–11.8 18.0 16.7 15.6–20.4 28.8 15.1 27.4–30.3 <0.01
Symptoms
Subjective symptoms 8.0 4.5 7.4–8.5 11.0 4.9 10.3–11.8 13.3 4.0 13.0–13.7 <0.01
Dyspnoea emotions 8.9 3.1 8.6–9.3 11.5 4.6 10.9–12.2 13.6 4.0 13.2–13.9 <0.01
Fatigue 32.6 11.6 31.3–34.0 38.0 10.3 36.4–39.4 42.4 9.5 41.5–43.3 <0.01
Data are expressed as mean, standard deviation (SD) and 95% confidence interval (CI).
aThe two subdomains from the main domain ‘Physiological functioning’ (i.e., BMI and FEV1 % predicted) were included as potential confounders in the
analysis.
bp values are from multilevel linear regression analysis for overall difference between the three cohorts.
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treatment in secondary care (hospital specialist setting) or even
tertiary care (pulmonary rehabilitation setting). Or, at least, in these
patients a detailed assessment is warranted that in addition to a
medical analysis also requires a detailed analysis of HS. Conversely,
part of the patients in secondary care may be treated adequately in
primary care by their general practitioner. We also found that COPD
patients in primary and secondary care showed marked hetero-
geneity, which means that not all these problems are present in all
individuals at any given time point. The marked heterogeneity is
































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1 NCSI health status subdomains per care level: distribution
of proportions of normal functioning, mild problems and severe
problems (%). a Primary care COPD cohort; b secondary care COPD
cohort; c tertiary care COPD cohort. QoL quality of life, HRQOL
health−related quality of life, Rel relation, Subimp subjective
impairment, Behimp behavioural impairment, Subcom subjective
symptoms, Dysemo dyspnoea emotions, Fat fatigue, NCSI Nijmegen
Clinical Screening Instrument.
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domains of HS: quality of life, functional impairment, and burden of
symptoms. Patients in tertiary care showed the most problems in
HS, but even in this highly specialized care setting there were also
some patients (6%) who showed no or only mild problems in terms
of subjective impairment, behavioural impairment and dyspnoea
emotions. This small group probably came with limited treatment
goals, often physiologically. Overall, our findings indicate that
patients with COPD vary from no problems in any to severe
problems in all eight HS subdomains. This heterogeneity requires a
personalized treatment approach. In addition, the heterogeneity
also shows the importance of a detailed assessment of HS in all
patients with COPD.
Regarding the first aim of our study (compare HS of COPD
patients in three care levels), we traced one previous study by Smid
et al. in which COPD-specific HS was compared between the three
levels of COPD care9. These authors reported that 68% of patients in
primary care, 90% in secondary care and 95% in tertiary care were
highly symptomatic based on their COPD Assessment Test (CAT)
score. Clinical COPD Questionnaire (CCQ) scores (measuring general
impact and cough10) and St George’s Respiratory Questionnaire for
COPD patient scores (measuring HS11) also worsened from primary
to tertiary care. Patients treated in tertiary care had the worst lung
function, more severe symptoms and more impaired HS9. Overall,
our results that are based on a much more comprehensive
assessment of HS using the NCSI are in line with the findings
reported by Smid and colleagues.
Regarding our second study aim (i.e. explore potential
determinants that may influence HS in COPD), we observed that
female patients in our combined cohorts experienced more
behavioural impairment and subjective symptoms than male
patients. Looking at the existing literature, an explanation for this
could be that, in general, female COPD patients experience more
problems due to feeling or being responsible for household tasks
compared to male patients12. On the other hand, COPD seems to
have a larger impact on symptoms and physical performance in
males than in females13. We also observed that younger patients
with COPD showed lower quality of life and more burden of
dyspnoea emotions than older patients. The literature tells us that
younger patients may perceive lower quality of life because of
their greater responsibilities related to work, family and/or
functional status14. Older patients are more likely to change their
expectations, may use different reference points to judge their
quality of life and may experience less impact of dyspnoea as a
result of tolerance of and adaptation to the disease15. Previous
evidence reported by Berry and colleagues suggests that age
modifies how patients with chronic respiratory diseases perceive
their impairments and the associated functional limitations, with
older patients tending to be more optimistic about their health14.
In contrast with this, we found that older patients experienced
more behavioural impairments than younger patients did. The
Fig. 2 Distribution of percentages of patients with severe
problems in the number of subdomains of health status as
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older patients in our study may have inappropriately attributed
their limitations to aging, or possibly (also) to comorbidities.
Finally, we observed that lower FEV1 % predicted was
associated with functional impairments and subjective symptoms.
Psychological factors significantly contribute to disease-specific
quality-of-life impairment in COPD and potentially explain the
mismatch between objective physiologic impairment and
patients’ experience of their disease16.
The main strength of our study is the large study population
(n= 906), combining HS and clinical data from COPD patients who
are treated in primary, secondary and tertiary care levels into one
study. Another strength is the use of the NCSI method, which
provides a detailed and evidence-based approach to study HS in
COPD. Assessing a patient’s HS is a prerequisite for personalized
COPD management. Other existing instruments usually measure HS
of COPD patients in a less comprehensive way10,11,17,18. None-
theless, a limitation of the study is that we did not include other HS
instruments (e.g. CAT or CCQ questionnaires) to compare the results
of the three COPD cohorts. A final limitation is the lack of (uniform)
clinical baseline data on comorbidity and exacerbation rate in the
three cohorts. More research is needed to understand which factors
also determine a COPD patient’s HS, both in a positive and negative
way, in order to achieve better personalized treatment.
In conclusion, our study showed that the proportion of COPD
patients with severe problems in HS is substantial. The highest
rate of HS problems was seen in patients in tertiary care, but a
substantial part of primary and secondary care patients also
showed severe HS problems. Knowing that, not all patients seem
to be managed at the level of care that would be the most
appropriate for them. The pooled cohort data showed female sex,
age, severity of airflow obstruction and BMI to be determinants of
one or more subdomains of HS. The results of our study imply that
detailed assessment of HS is warranted, not only to obtain a better
understanding of which care level a COPD patient needs for
optimal treatment but also to support healthcare professionals in
optimizing and tailoring chronic COPD care.
METHODS
Study subjects
In this observational cross-sectional study data on COPD, patients’ HS was
collected between 2012 and 2017 in three different care settings in the
Netherlands: primary care, secondary care, and tertiary care. All data were
collected as a part of usual care for the patients involved. We studied the
following three cohorts.
Primary care cohort. HS data of all 289 patients with COPD receiving care
from GPs (i.e. without involvement of a chest physician in the patient’s
management) in 8 practices in the general practice network of the
Department of Primary and Community Care of the Radboud University
Medical Center in Nijmegen were used. In this primary care cohort,
patients were included between February 2013 and February 2017.
Secondary care cohort. HS data of 184 patients who were referred by their
GP to a secondary care chest physician at the Franciscus Gasthuis &
Vlietland in the city of Rotterdam were used. The cohort consisted of all
consecutive patients with a chest-physician-confirmed diagnosis of COPD
referred in 2012, 2013 or 2014, without further selection.
Tertiary care cohort. HS data of 433 patients with COPD referred to and
enrolled in the Pulmonary rehabilitation programme Dekkerswald of the
Radboud University Medical Center, Nijmegen between July 2012 and July
2016 were used. The pulmonary rehabilitation programme is a multi-
disciplinary intervention consisting of patient-tailored therapies to optimize
Table 5. Subdomains of health status and their definition and included instruments of the Nijmegen Clinical Screening Instrument (NCSI)1,2.





Airflow obstruction Post-bronchodilator FEV1
% predicted
Body composition Body mass index
Quality of life General Quality of Life Mood and the satisfaction of a person
with his/her life as a whole
BDI Primary Care 7 1–101.6
Satisfaction with Life Scale 5
Health-related Quality
of Life






Satisfaction relations Satisfaction with the (absent) relationships




Functional impairment Subjective impairment Experienced degree of impairment in
general
QoL-RiQ General Activities 4 4–28
Behavioural impairment Extent to which a person cannot perform
specific and concrete activities as a result
of having the disease
SIP Home Management 10 0–135.5
SIP Ambulation 12





PARS-D Global Dyspnea Burden 1
Dyspnoea emotions Level of frustration and anxiety a person
experiences when dyspnoeic
DEQ Frustration 3 6–24
DEQ Anxiety 3
Fatigue Level of experienced fatigue CIS Subjective fatigue 8 8–56
BDI Beck’s Depression Inventory, CIS Checklist Individual Strength, DEQ Dyspnea Emotions Questionnaire, FEV1 forced expiratory volume in 1 s, PARS-D Physical
Activity Rating Scale-Dyspnea, QoL-RiQ Quality of Life for Respiratory Illness Questionnaire, SIP Sickness Impact Profile.
aPhysiological functioning: airflow obstruction and body composition values were used as confounders or determinants of health status in the current study.
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and maintain physical and psychological condition through physical training
and by teaching the patient adequate self-management skills19.
Inclusion criteria that applied to all three cohorts were: diagnosis of COPD
and age ≥40 years. Patients who were unable to speak or read Dutch and/or
had incomplete data were excluded. In case more than one NCSI-based HS
assessment had been performed in a particular patient, only the data of the
first assessment were used. Data were de-identified at the source before
further analysis.
Due to privacy regulations, we could not check whether overlap between
the cohorts existed, i.e. whether one or more patients had been included in
more than one of the cohorts. This is, however, highly unlikely because (i)
the patients in the secondary care cohort were from a very different
geographical area (i.e. city of Rotterdam and surroundings in the western
part of the country) than the patients in the primary and tertiary care
cohorts (city of Nijmegen and surroundings in the eastern part of the
country) and (ii) the patients in the primary care cohort had to be managed
by their GP only, i.e. without involvement of a secondary or tertiary care
chest physician.
Because the aims of our study were explorative in nature, no a priori
assumptions with regard to (potential) differences in HS subdomains
between the three cohorts were made and a sample size calculation was not
applicable.
Data collection
During routine patient visits, data regarding sex, age, BMI and lung
function (i.e. FEV1 expressed as percentage of predicted) were system-
atically collected. The NCSI6,20,21 was used to measure patients’ HS. The
NCSI is a battery of existing instruments that was empirically composed in
such a way that overlap between instruments was avoided and that a wide
variety of aspects of HS are measured. Overall, the NCSI measures ten
subdomains of HS covering the main domains quality of life (3 sub-
domains), functional impairment (2 subdomains), symptoms (3 subdo-
mains) and physiological functioning (2 subdomains). Table 5 shows the
tests and instruments included in the NCSI. Normative data have been
collected in healthy subjects and several cohorts of patients with COPD to
identify cut-off scores for normal functioning, mild problems and severe
problems6,21. For each instrument, the score belonging to 80th percentile
of a healthy control population was used as the maximum score of normal
functioning, and the score belonging to the 20th percentile of the
pulmonary rehabilitation patients was used as the minimum score
representing clinically relevant problems20. In all subdomains, a higher
score indicates more impairment. Patients completed the NCSI before their
visit to the general practice, hospital or pulmonary rehabilitation centre,
either online at home or using a computer at the healthcare facility.
Scoring of the items was automated.
Ethics approval and consent
We applied the Code of Conduct for Medical Research issued by the Dutch
Council of the Federation of Medical Scientific Societies22 to this research.
Because the NCSI and demographic and clinical data were collected as a
part of routine patient care and no intervention or course of action was
imposed on patients, no ethics approval was required. Patients could
refuse the use of their de-identified data for scientific research purposes
and have their data removed from the research database.
Statistical analyses
Descriptive statistics are presented as mean, standard deviation (SD),
frequencies and percentages depending on the scale on which the
variables are measured. Because of the hierarchical structure of our study
(patients nested within general practices and hospitals), we performed
multilevel linear regression analysis to test differences between the three
cohorts on eight of the ten NCSI subdomains (the two subdomains
regarding physiological functioning, i.e. BMI, and FEV1 % predicted, were
not analysed as such) while controlling for sex, age, BMI and FEV1 %
predicted. We performed a model with a random intercept and all other
variables fixed. A similar model was used to analyse patient characteristics
as possible determinants of HS in the combined data of the three cohorts.
To avoid increase in type 1 error due to multiple testing when comparing
the subdomain scores between the three cohorts, we applied a Bonferroni
correction: p < 0.00625 (i.e. 0.05/8 subdomains) was considered statistically
significant, based on two-sided testing. Analyses were performed using
IBM SPSS version 25.0 (SPSS Inc., Chicago, USA).
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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